StockNews.com assumed coverage on shares of Ekso Bionics (NASDAQ:EKSO – Free Report) in a research note issued to investors on Friday morning. The brokerage issued a hold rating on the stock.
Several other research analysts have also recently weighed in on EKSO. Lake Street Capital began coverage on shares of Ekso Bionics in a report on Monday, June 24th. They set a buy rating and a $2.50 price objective for the company. HC Wainwright raised their price target on Ekso Bionics from $9.25 to $10.00 and gave the stock a buy rating in a research note on Tuesday, April 30th.
Get Our Latest Stock Report on EKSO
Ekso Bionics Stock Performance
Ekso Bionics (NASDAQ:EKSO – Get Free Report) last announced its quarterly earnings results on Monday, April 29th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.04). The firm had revenue of $3.76 million for the quarter, compared to the consensus estimate of $4.99 million. Ekso Bionics had a negative net margin of 79.48% and a negative return on equity of 95.36%. During the same period last year, the business earned ($0.33) EPS. Sell-side analysts anticipate that Ekso Bionics will post -0.43 EPS for the current fiscal year.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Ekso Bionics stock. Strategic Wealth Investment Group LLC lifted its stake in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO – Free Report) by 21.8% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 51,950 shares of the company’s stock after purchasing an additional 9,285 shares during the quarter. Strategic Wealth Investment Group LLC owned about 0.37% of Ekso Bionics worth $130,000 at the end of the most recent reporting period. 6.42% of the stock is currently owned by hedge funds and other institutional investors.
Ekso Bionics Company Profile
Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.
Recommended Stories
- Five stocks we like better than Ekso Bionics
- What is a Stock Market Index and How Do You Use Them?
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- What is the Australian Securities Exchange (ASX)
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- Industrial Products Stocks Investing
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.